UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Scytonemin--a marine natural product inhibitor of kinases key in hyperproliferative inflammatory diseases

Inflammation research, 2002-02, Vol.51 (2), p.112-114

2002

Volltextzugriff (PDF)

Human Calcium-independent Phospholipase A2 Mediates Lymphocyte Proliferation

The Journal of biological chemistry, 2000-11, Vol.275 (46), p.35692-35698

2000

Volltextzugriff (PDF)

The human polo-like kinase, PLK, regulates cdc2/cyclin B through phosphorylation and activation of the cdc25C phosphatase

Cellular signalling, 2000-06, Vol.12 (6), p.405-411

2000

Volltextzugriff (PDF)

gene (pks2) encoding a putative 6-methylsalicylic acid synthase from Glarea lozoyensis

Molecular genetics and genomics : MGG, 2005-04, Vol.273 (2), p.207-216

2005

Volltextzugriff (PDF)

Small-molecule inhibitors of NF- κB for the treatment of inflammatory joint disease

Current Opinion in Pharmacology, 2002-06, Vol.2 (3), p.316-321

2002

Volltextzugriff (PDF)

Suppression of monocyte 85-kDa phospholipase A2 by antisense and effects on endotoxin-induced prostaglandin biosynthesis

The Journal of biological chemistry, 1994-10, Vol.269 (42), p.25999-26005

1994

Volltextzugriff (PDF)

Differential effects of SB 242235, a selective p38 mitogen-activated protein kinase inhibitor, on IL-1 treated bovine and human cartilage/chondrocyte cultures

Osteoarthritis and cartilage, 2000-11, Vol.8 (6), p.434-443

2000

Volltextzugriff (PDF)

1247P Management of infusion-related reactions (IRRs) in patients receiving amivantamab

Annals of oncology, 2021-09, Vol.32, p.S981-S982

2021

Volltextzugriff (PDF)

P76.74 PAPILLON: Randomized Phase 3 Study of Amivantamab Plus Chemotherapy vs Chemotherapy Alone in EGFR Exon20ins NSCLC

Journal of thoracic oncology, 2021-03, Vol.16 (3), p.S621-S621

2021

Volltextzugriff (PDF)

P15.03 A Phase 1/1b Study of Lazertinib as Monotherapy and in Combination with Amivantamab in Advanced EGFR-Mutated NSCLC

Journal of thoracic oncology, 2021-03, Vol.16 (3), p.S344-S345

2021

Volltextzugriff (PDF)

P76.73 MARIPOSA: Randomized Phase 3 Study of First-line Amivantamab + Lazertinib vs Osimertinib vs Lazertinib in EGFR-mutant NSCLC

Journal of thoracic oncology, 2021-03, Vol.16 (3), p.S620-S621

2021

Volltextzugriff (PDF)

OA15.03 Amivantamab in Non-small Cell Lung Cancer (NSCLC) with MET Exon 14 Skipping (METex14) Mutation: Initial Results from CHRYSALIS

Journal of thoracic oncology, 2021-10, Vol.16 (10), p.S874-S875

2021

Volltextzugriff (PDF)

OA21.04 Amivantamab in Patients with Advanced NSCLC and MET Exon 14 Skipping Mutation: Results from the CHRYSALIS Study

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S93-S94

2023

Volltextzugriff (PDF)

P86.12 Cardiac Safety Assessment of Lazertinib in Patients with EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer

Journal of thoracic oncology, 2021-03, Vol.16 (3), p.S677-S678

2021

Volltextzugriff (PDF)

P1.01-94 JNJ-61186372, an EGFR-cMet Bispecific Antibody, in EGFR Exon 20 Insertion-Driven Advanced NSCLC

Journal of thoracic oncology, 2019-10, Vol.14 (10), p.S397-S398

2019

Volltextzugriff (PDF)

OA04.04 Amivantamab in Post-platinum EGFR Exon 20 Insertion Mutant Non-small Cell Lung Cancer

Journal of thoracic oncology, 2021-03, Vol.16 (3), p.S108-S109

2021

Volltextzugriff (PDF)

Anti-human RP105 sera induces lymphocyte proliferation

Journal of leukocyte biology, 1999-01, Vol.65 (1), p.43-49

1999

Volltextzugriff (PDF)

SB 203347, an inhibitor of 14 kDa phospholipase A2, alters human neutrophil arachidonic acid release and metabolism and prolongs survival in murine endotoxin shock

The Journal of pharmacology and experimental therapeutics, 1995-09, Vol.274 (3), p.1254

1995

Volltextzugriff (PDF)

Effects of scalaradial, a type II phospholipase A2 inhibitor, on human neutrophil arachidonic acid mobilization and lipid mediator formation

The Journal of pharmacology and experimental therapeutics, 1994-02, Vol.268 (2), p.709

1994

Volltextzugriff (PDF)

Modulation of human monocyte activities by tranilast, SB 252218, a compound demonstrating efficacy in restenosis

The Journal of pharmacology and experimental therapeutics, 2000-12, Vol.295 (3), p.1061

2000

Volltextzugriff (PDF)

Decreased nuclear factor-κB DNA binding activity following permanent focal cerebral ischaemia in the rat

Neuroscience letters, 2000-07, Vol.288 (1), p.45-48

2000

Volltextzugriff (PDF)

An indolocarbazole inhibitor of human checkpoint kinase (Chk1) abrogates cell cycle arrest caused by DNA damage

Cancer research (Chicago, Ill.), 2000-02, Vol.60 (3), p.566-572

2000

Volltextzugriff (PDF)

Coexistence of two biochemically distinct phospholipase A2 activities in human platelet, monocyte, and neutrophil

Biochemistry and cell biology, 1993-07, Vol.71 (7-8), p.331

1993

Volltextzugriff (PDF)

Attenuation of Murine Collagen-Induced Arthritis by a Novel, Potent, Selective Small Molecule Inhibitor of IκB Kinase 2, TPCA-1 (2-[(Aminocarbonyl)amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide), Occurs via Reduction of Proinflammatory Cytokines and Antigen-Induced T Cell Proliferation

The Journal of pharmacology and experimental therapeutics, 2005-01, Vol.312 (1), p.373-381

2005

Volltextzugriff (PDF)

Characterization of phospholipase A2 from human nasal lavage

American journal of respiratory cell and molecular biology, 1994-07, Vol.11 (1), p.108-113

1994

Volltextzugriff (PDF)

1 – 25 von 97

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(75)
Mit Volltextzugriff
(64)

Publikationsform

Sprache

Englisch
(96)
Japanisch
(1)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

Scytonemin--a marine natural product inhibitor of kinases key in hyperproliferative inflammatory diseases

Human Calcium-independent Phospholipase A2 Mediates Lymphocyte Proliferation

The human polo-like kinase, PLK, regulates cdc2/cyclin B through phosphorylation and activation of the cdc25C phosphatase

gene (pks2) encoding a putative 6-methylsalicylic acid synthase from Glarea lozoyensis

Small-molecule inhibitors of NF- κB for the treatment of inflammatory joint disease

Suppression of monocyte 85-kDa phospholipase A2 by antisense and effects on endotoxin-induced prostaglandin biosynthesis

Differential effects of SB 242235, a selective p38 mitogen-activated protein kinase inhibitor, on IL-1 treated bovine and human cartilage/chondrocyte cultures

1247P Management of infusion-related reactions (IRRs) in patients receiving amivantamab

P76.74 PAPILLON: Randomized Phase 3 Study of Amivantamab Plus Chemotherapy vs Chemotherapy Alone in EGFR Exon20ins NSCLC

P15.03 A Phase 1/1b Study of Lazertinib as Monotherapy and in Combination with Amivantamab in Advanced EGFR-Mutated NSCLC

P76.73 MARIPOSA: Randomized Phase 3 Study of First-line Amivantamab + Lazertinib vs Osimertinib vs Lazertinib in EGFR-mutant NSCLC

OA15.03 Amivantamab in Non-small Cell Lung Cancer (NSCLC) with MET Exon 14 Skipping (METex14) Mutation: Initial Results from CHRYSALIS

OA21.04 Amivantamab in Patients with Advanced NSCLC and MET Exon 14 Skipping Mutation: Results from the CHRYSALIS Study

P86.12 Cardiac Safety Assessment of Lazertinib in Patients with EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer

P1.01-94 JNJ-61186372, an EGFR-cMet Bispecific Antibody, in EGFR Exon 20 Insertion-Driven Advanced NSCLC

OA04.04 Amivantamab in Post-platinum EGFR Exon 20 Insertion Mutant Non-small Cell Lung Cancer

Anti-human RP105 sera induces lymphocyte proliferation

SB 203347, an inhibitor of 14 kDa phospholipase A2, alters human neutrophil arachidonic acid release and metabolism and prolongs survival in murine endotoxin shock

Effects of scalaradial, a type II phospholipase A2 inhibitor, on human neutrophil arachidonic acid mobilization and lipid mediator formation

Modulation of human monocyte activities by tranilast, SB 252218, a compound demonstrating efficacy in restenosis

Decreased nuclear factor-κB DNA binding activity following permanent focal cerebral ischaemia in the rat

An indolocarbazole inhibitor of human checkpoint kinase (Chk1) abrogates cell cycle arrest caused by DNA damage

Coexistence of two biochemically distinct phospholipase A2 activities in human platelet, monocyte, and neutrophil

Attenuation of Murine Collagen-Induced Arthritis by a Novel, Potent, Selective Small Molecule Inhibitor of IκB Kinase 2, TPCA-1 (2-[(Aminocarbonyl)amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide), Occurs via Reduction of Proinflammatory Cytokines and Antigen-Induced T Cell Proliferation

Characterization of phospholipase A2 from human nasal lavage

Suchergebnisse filtern